The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Mosunetuzumab in B-NHL R/R to CAR-T
Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, outlines recent data on mosunetuzumab, a bispecific antibody targeting both CD3 and CD20, in patients with B-cell non-Hodgkin lymphoma (NHL), who are relapsed/refractory to CAR-T therapies, or for those who do not have access to CAR-T. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
